Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage.

Sridharan S, Thompson LDR, Purgina B, Sturgis CD, Shah AA, Burkey B, Tuluc M, Cognetti D, Xu B, Higgins K, Hernandez-Prera JC, Guerrero D, Bundele MM, Kim S, Duvvuri U, Ferris RL, Gooding WE, Chiosea SI.

Cancer. 2019 Sep 15;125(18):3198-3207. doi: 10.1002/cncr.32199. Epub 2019 Jun 7.

PMID:
31174238
2.

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT.

Theodoraki MN, Yerneni S, Gooding WE, Ohr J, Clump DA, Bauman JE, Ferris RL, Whiteside TL.

Oncoimmunology. 2019 Apr 24;8(7):1593805. doi: 10.1080/2162402X.2019.1593805. eCollection 2019.

3.

Hypopharyngeal cancer treatment: Does initial surgery confer survival benefit?

Tassler AB, Gooding WE, Ferris RL.

Head Neck. 2019 Jul;41(7):2167-2173. doi: 10.1002/hed.25687. Epub 2019 Feb 19.

PMID:
30779398
4.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR.

J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25.

5.

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.

Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE.

JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.

6.

Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.

Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A.

Cancer. 2018 Oct 1;124(19):3881-3889. doi: 10.1002/cncr.31651. Epub 2018 Oct 6.

PMID:
30291796
7.

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer.

Lu S, Concha-Benavente F, Shayan G, Srivastava RM, Gibson SP, Wang L, Gooding WE, Ferris RL.

Oral Oncol. 2018 Mar;78:186-193. doi: 10.1016/j.oraloncology.2018.01.019. Epub 2018 Feb 20.

8.

Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.

Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana-Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE.

Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.

9.

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients.

Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL.

Clin Cancer Res. 2018 Feb 15;24(4):896-905. doi: 10.1158/1078-0432.CCR-17-2664. Epub 2017 Dec 12.

10.

Multicenter outcomes of robotic reconstruction during the early learning curve for minimally-invasive pancreaticoduodenectomy.

Watkins AA, Kent TS, Gooding WE, Boggi U, Chalikonda S, Kendrick ML, Walsh RM, Zeh HJ 3rd, Moser AJ.

HPB (Oxford). 2018 Feb;20(2):155-165. doi: 10.1016/j.hpb.2017.08.032. Epub 2017 Sep 29.

11.

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL.

Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.

12.

Solitary Fibrous Tumors of the Head and Neck: A Multi-Institutional Clinicopathologic Study.

Smith SC, Gooding WE, Elkins M, Patel RM, Harms PW, McDaniel AS, Palanisamy N, Uram-Tuculescu C, Balzer BB, Lucas DR, Seethala RR, McHugh JB.

Am J Surg Pathol. 2017 Dec;41(12):1642-1656. doi: 10.1097/PAS.0000000000000940.

13.

Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.

Lontos K, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Gooding WE, Humar A, Boyiadzis M.

Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13052. Epub 2017 Aug 9.

PMID:
28710776
14.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE.

Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.

15.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

16.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

17.

Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx.

Albergotti WG, Gooding WE, Kubik MW, Geltzeiler M, Kim S, Duvvuri U, Ferris RL.

JAMA Otolaryngol Head Neck Surg. 2017 Jun 1;143(6):542-548. doi: 10.1001/jamaoto.2016.4132.

18.

Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.

Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR.

PLoS One. 2016 Nov 17;11(11):e0166185. doi: 10.1371/journal.pone.0166185. eCollection 2016.

19.

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A.

Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.

20.

Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.

Chiosea SI, Thompson LD, Weinreb I, Bauman JE, Mahaffey AM, Miller C, Ferris RL, Gooding WE.

Cancer. 2016 Oct 15;122(20):3136-3144. doi: 10.1002/cncr.30179. Epub 2016 Jul 5.

21.

STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.

Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR.

Cancer Prev Res (Phila). 2016 Aug;9(8):657-63. doi: 10.1158/1940-6207.CAPR-16-0089. Epub 2016 Jun 7.

22.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
23.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

24.

Electromagnetic Navigation Bronchoscopy-Guided Dye Marking for Thoracoscopic Resection of Pulmonary Nodules.

Awais O, Reidy MR, Mehta K, Bianco V, Gooding WE, Schuchert MJ, Luketich JD, Pennathur A.

Ann Thorac Surg. 2016 Jul;102(1):223-9. doi: 10.1016/j.athoracsur.2016.02.040. Epub 2016 May 5.

PMID:
27157054
25.

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA.

JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.

26.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86862. Epub 2016 Apr 1. No abstract available.

27.

Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.

Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL.

Sci Rep. 2016 Feb 4;6:20254. doi: 10.1038/srep20254.

28.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Jan;126(1):169-80. doi: 10.1172/JCI82066. Epub 2015 Nov 30. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1606.

29.

Stereotactic Radiosurgery/Stereotactic Body Radiotherapy for Recurrent Lung Neoplasm: An Analysis of Outcomes in 100 Patients.

Pennathur A, Luketich JD, Heron DE, Schuchert MJ, Bianco V, Clump D, Burton S, Abbas G, Gooding WE, Ozhasoglu C, Landreneau RJ, Christie NA.

Ann Thorac Surg. 2015 Dec;100(6):2019-24. doi: 10.1016/j.athoracsur.2015.04.113. Epub 2015 Sep 19.

PMID:
26387725
30.

Thoracic Esophageal Diverticula: A 15-Year Experience of Minimally Invasive Surgical Management.

Macke RA, Luketich JD, Pennathur A, Bianco V, Awais O, Gooding WE, Christie NA, Schuchert MJ, Nason KS, Levy RM.

Ann Thorac Surg. 2015 Nov;100(5):1795-802. doi: 10.1016/j.athoracsur.2015.04.122. Epub 2015 Sep 19.

PMID:
26387723
31.

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.

Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN.

Thyroid. 2015 Nov;25(11):1217-23. doi: 10.1089/thy.2015.0305. Epub 2015 Sep 10.

32.

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.

Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR.

Clin Cancer Res. 2015 Oct 15;21(20):4597-606. doi: 10.1158/1078-0432.CCR-14-3338. Epub 2015 Jul 2.

33.

Reply to Letter: "Poorer Survival for Stage IIa Patients After Minimally Invasive Esophagectomy".

Pennathur A, Gooding WE, Nason KS, Luketich JD.

Ann Surg. 2015 Aug;262(2):e45-7. doi: 10.1097/SLA.0000000000000864. No abstract available.

PMID:
25590498
34.

Roux-en-Y near esophagojejunostomy for failed antireflux operations: outcomes in more than 100 patients.

Awais O, Luketich JD, Reddy N, Bianco V, Levy RM, Schuchert MJ, Gooding WE, Crist LR, Landreneau RJ, Pennathur A.

Ann Thorac Surg. 2014 Dec;98(6):1905-11; discussion 1911-3. doi: 10.1016/j.athoracsur.2014.07.004. Epub 2014 Oct 29.

PMID:
25442998
35.

Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.

Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN.

Cancer. 2014 Dec 1;120(23):3627-34. doi: 10.1002/cncr.29038. Epub 2014 Sep 10.

36.

Pectoralis major myofascial onlay and myocutaneous flaps and pharyngocutaneous fistula in salvage laryngectomy.

Gilbert MR, Sturm JJ, Gooding WE, Johnson JT, Kim S.

Laryngoscope. 2014 Dec;124(12):2680-6. doi: 10.1002/lary.24796. Epub 2014 Jul 30.

37.

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR.

Clin Cancer Res. 2014 Jun 15;20(12):3289-98. doi: 10.1158/1078-0432.CCR-13-3360. Epub 2014 Apr 11.

38.

Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.

Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, Grandis JR.

Mol Cancer Res. 2014 Apr;12(4):571-82. doi: 10.1158/1541-7786.MCR-13-0396. Epub 2014 Jan 14.

39.

Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.

Sankunny M, Parikh RA, Lewis DW, Gooding WE, Saunders WS, Gollin SM.

Genes Chromosomes Cancer. 2014 Feb;53(2):129-43. doi: 10.1002/gcc.22125. Epub 2013 Nov 25.

40.

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A.

Anticancer Res. 2013 Oct;33(10):4475-81.

41.

Early squamous cell carcinoma of the oral tongue: comparing margins obtained from the glossectomy specimen to margins from the tumor bed.

Chang AM, Kim SW, Duvvuri U, Johnson JT, Myers EN, Ferris RL, Gooding WE, Seethala RR, Chiosea SI.

Oral Oncol. 2013 Nov;49(11):1077-82. doi: 10.1016/j.oraloncology.2013.07.013. Epub 2013 Aug 27.

PMID:
23988568
42.

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Apr 1;19(7):1858-72. doi: 10.1158/1078-0432.CCR-12-2426. Epub 2013 Feb 26.

43.

Gene expression profiles in esophageal adenocarcinoma predict survival after resection.

Pennathur A, Xi L, Litle VR, Gooding WE, Krasinskas A, Landreneau RJ, Godfrey TE, Luketich JD.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):505-12; discussion 512-3. doi: 10.1016/j.jtcvs.2012.10.031.

44.
45.

Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR.

Clin Cancer Res. 2012 Sep 15;18(18):4986-96. doi: 10.1158/1078-0432.CCR-12-0792. Epub 2012 Jul 23.

46.

Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL.

Oral Oncol. 2012 Nov;48(11):1136-45. doi: 10.1016/j.oraloncology.2012.05.015. Epub 2012 Jun 23.

47.

First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR.

Cancer Discov. 2012 Aug;2(8):694-705. doi: 10.1158/2159-8290.CD-12-0191. Epub 2012 Jun 20.

48.

Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring.

Beswick DM, Gooding WE, Johnson JT, Branstetter BF 4th.

Laryngoscope. 2012 Jul;122(7):1512-7. doi: 10.1002/lary.23341. Epub 2012 Jun 8.

49.

Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

Rao A, Taylor JL, Chi-Sabins N, Kawabe M, Gooding WE, Storkus WJ.

Cancer Res. 2012 Jul 1;72(13):3196-206. doi: 10.1158/0008-5472.CAN-12-0538. Epub 2012 May 2. Erratum in: Cancer Res. 2012 Oct 15;72(20):5431.

50.

Bile exposure inhibits expression of squamous differentiation genes in human esophageal epithelial cells.

Reveiller M, Ghatak S, Toia L, Kalatskaya I, Stein L, D'Souza M, Zhou Z, Bandla S, Gooding WE, Godfrey TE, Peters JH.

Ann Surg. 2012 Jun;255(6):1113-20. doi: 10.1097/SLA.0b013e3182512af9.

PMID:
22498892

Supplemental Content

Loading ...
Support Center